Biophagy presents “Examining the Potency of Potential Autophagy Inducing Drugs,” at a UNM Discovery Symposium By jordan|2022-03-22T20:33:35+00:00February 1, 2022|2020-announcements|0 Comments Read More
Biophagy initiates a new program to study its proprietary compounds in SARS-CoV-2 (covid-19). These studies will be conducted by Dr. Steven Bradfute at UNM. By jordan|2022-03-22T20:33:48+00:00February 1, 2022|2020-announcements|0 Comments Read More
Biophagy announces the addition of Bhaskar Suda, PhD, to its team of consultants. Bhaskar will develop and run autophagy measuring assays and study proprietary compounds in neurodegenerative disorders. By jordan|2022-02-01T19:10:56+00:00February 1, 2022|2020-announcements|0 Comments Read More
Biophagy institutes a new division, CellWatch™, to develop its over-the-counter/direct-to-consumer products for the stimulation and measurement of autophagy in individuals. By jordan|2022-03-22T20:37:21+00:00February 1, 2022|2020-announcements|0 Comments Read More
Biophagy presents “Potential of Proprietary Molecules for Inducing Autophagy and Enhancing Antibiotic Treatment of Tuberculosis” at the Keystone Symposium, Tuberculosis: Immunity and Immune Evasion,” Santa Fe, NM By jordan|2022-02-01T19:10:32+00:00February 1, 2022|2020-announcements|0 Comments Read More